IL156919A0 - Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv - Google Patents
Mixture of recombinant vaccinia vectors as polyenv vaccines for hivInfo
- Publication number
- IL156919A0 IL156919A0 IL15691997A IL15691997A IL156919A0 IL 156919 A0 IL156919 A0 IL 156919A0 IL 15691997 A IL15691997 A IL 15691997A IL 15691997 A IL15691997 A IL 15691997A IL 156919 A0 IL156919 A0 IL 156919A0
- Authority
- IL
- Israel
- Prior art keywords
- hiv
- mixture
- recombinant vaccinia
- vaccinia vectors
- polyenv vaccines
- Prior art date
Links
- 206010046865 Vaccinia virus infection Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 208000007089 vaccinia Diseases 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/590,288 US5741492A (en) | 1996-01-23 | 1996-01-23 | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
IL125497A IL125497A (en) | 1996-01-23 | 1997-01-23 | Vaccroy's Immunogenic Mixture - and its Combinant Officers with Multiple Variations of HIV Envelope Protein |
PCT/US1997/000669 WO1997027311A1 (fr) | 1996-01-23 | 1997-01-23 | Melange de vecteurs de recombinaison du virus de la vaccine utilises comme vaccins polyenv contre le vih |
Publications (1)
Publication Number | Publication Date |
---|---|
IL156919A0 true IL156919A0 (en) | 2004-02-08 |
Family
ID=24361647
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL125497A IL125497A (en) | 1996-01-23 | 1997-01-23 | Vaccroy's Immunogenic Mixture - and its Combinant Officers with Multiple Variations of HIV Envelope Protein |
IL15691997A IL156919A0 (en) | 1996-01-23 | 1997-01-23 | Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL125497A IL125497A (en) | 1996-01-23 | 1997-01-23 | Vaccroy's Immunogenic Mixture - and its Combinant Officers with Multiple Variations of HIV Envelope Protein |
Country Status (29)
Country | Link |
---|---|
US (3) | US5741492A (fr) |
EP (2) | EP0876498B1 (fr) |
JP (2) | JP2000504326A (fr) |
KR (1) | KR100571479B1 (fr) |
CN (1) | CN1229501C (fr) |
AP (1) | AP1200A (fr) |
AT (1) | ATE278790T1 (fr) |
AU (1) | AU709174B2 (fr) |
BG (1) | BG64711B1 (fr) |
BR (1) | BR9707611A (fr) |
CA (1) | CA2243570C (fr) |
CZ (1) | CZ296575B6 (fr) |
DE (1) | DE69731075T2 (fr) |
DK (1) | DK0876498T3 (fr) |
EA (1) | EA002390B1 (fr) |
ES (1) | ES2230596T3 (fr) |
GE (1) | GEP20032902B (fr) |
HK (1) | HK1016218A1 (fr) |
HU (2) | HU224344B1 (fr) |
IL (2) | IL125497A (fr) |
NO (1) | NO322261B1 (fr) |
NZ (1) | NZ331024A (fr) |
OA (1) | OA10814A (fr) |
PL (1) | PL188641B1 (fr) |
PT (1) | PT876498E (fr) |
RO (1) | RO120268B1 (fr) |
TR (1) | TR199801418T2 (fr) |
UA (1) | UA73712C2 (fr) |
WO (1) | WO1997027311A1 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7488485B2 (en) * | 2003-09-16 | 2009-02-10 | University Of Kansas Medical Center | DNA vaccine compositions and methods of use |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
US6919318B1 (en) * | 1998-04-22 | 2005-07-19 | Chiron Corporation | Enhancing immune responses to genetic immunization by using a chemokine |
WO1999061049A2 (fr) * | 1998-05-22 | 1999-12-02 | University Of Massachusetts Medical Center | Modele d'infection par un germe pathogene utilisant l'administration d'acides nucleiques |
US6562800B1 (en) * | 1998-10-30 | 2003-05-13 | University Of Southern California | Use of immunopotentiating sequences for inducing immune response |
US6759237B1 (en) * | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
ES2340230T3 (es) * | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | Vectores viricos y sus procedimientos de preparacion y administracion. |
US6602705B1 (en) * | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
AU2487300A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
JP4776075B2 (ja) * | 1998-12-31 | 2011-09-21 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改変hivenvポリペプチド |
US6783762B1 (en) * | 1999-01-28 | 2004-08-31 | Stichting Biomedical Primate Research Centre | Product and method for obtaining specific immunization with one or more antigens |
DE19907485B4 (de) * | 1999-02-12 | 2008-01-17 | Strathmann Ag & Co. | Virus-Vakzine |
US6420545B1 (en) * | 1999-05-24 | 2002-07-16 | The Trustees Of The University Of Pennsylvania | CD4-independent HIV envelope proteins as vaccines and therapeutics |
AU3793701A (en) * | 1999-11-29 | 2001-06-04 | Orchid Biosciences, Inc. | Methods of identifying optimal drug combinations and compositions thereof |
US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
EP2388015A1 (fr) | 2000-03-02 | 2011-11-23 | Emory University | Vecteurs d'expression de l'ADN et procédés d'utilisation |
CA2417240A1 (fr) * | 2000-08-07 | 2002-02-14 | Sloan-Kettering Institute For Cancer Research | Procede et composition d'immunisation utilisant des pools melanges d'acides nucleiques ou de peptides mutes |
EP2198882A3 (fr) * | 2001-01-12 | 2010-10-13 | Novartis Vaccines and Diagnostics, Inc. | Immunisation des muqueuses par acide nucléique |
DK1372710T3 (da) * | 2001-03-08 | 2010-01-18 | Us Gov Health & Human Serv | MVA der udtrykker modificeret HIV-kappe-, Gag- og Pol-gener |
US7211659B2 (en) * | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP2292772A1 (fr) * | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
AU2002316578A1 (en) * | 2001-08-31 | 2003-03-18 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US20070269456A1 (en) * | 2001-11-05 | 2007-11-22 | Lasher Alfred W | DNA-based plasmid formulations and vaccines and prophylactics containing the same |
US20030228327A1 (en) * | 2001-11-05 | 2003-12-11 | Lasher Alfred W. | DNA-based plasmid formulations and vaccines and prophylactics containing the same |
CN1596126A (zh) | 2001-11-30 | 2005-03-16 | 埃西斯创新有限公司 | 疫苗 |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
US20040106566A1 (en) * | 2002-05-17 | 2004-06-03 | Shi-Lung Lin | RNA-splicing and processing-directed gene silencing and the relative applications thereof |
CA2492598C (fr) * | 2002-07-18 | 2013-12-17 | University Of Washington | Purification rapide et efficace de t-lymphocytes specifiques au hsv et antigenes a hsv identifies par ce procede |
CA2505583C (fr) * | 2002-12-03 | 2014-07-15 | University Of Massachusetts | Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination |
US7658927B2 (en) * | 2003-05-12 | 2010-02-09 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against FIV infection |
AU2004238367A1 (en) | 2003-05-12 | 2004-11-25 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against FIV infection |
US8076060B2 (en) * | 2003-08-04 | 2011-12-13 | Emil William Chynn | Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma |
JP2007505130A (ja) * | 2003-09-09 | 2007-03-08 | バイレクシス コーポレイション | ヒトにおいてhivに対する免疫応答を生成するための、レンチウイルスベクターベースのアプローチ |
CA2539021A1 (fr) * | 2003-09-15 | 2005-03-31 | Chiron Corporation | Approches combinees pour produire des reponses immunitaires |
WO2005034992A2 (fr) * | 2003-09-15 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mecanismes pour ameliorer l'etendue de la reponse immunitaire de brins et de variantes differentes de vih |
US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
US7622125B2 (en) | 2004-05-05 | 2009-11-24 | Novartis Vaccines And Diagnostics, Inc. | Polycistronic HIV vector constructs |
EP1773858B1 (fr) * | 2004-05-27 | 2016-06-22 | Janssen Biotech, Inc. | Antigene specifique de la prostate du singe cynomolgus |
EP1773406A4 (fr) * | 2004-06-15 | 2008-09-03 | Centocor Inc | Procede de criblage d'agents contre la maladie de la prostate chez l'homme |
JP4772045B2 (ja) * | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Cmv/r核酸コンストラクトを含むaidsに対するワクチン |
US20080085261A1 (en) * | 2004-10-19 | 2008-04-10 | Haynes Barton F | Vaccine Adjuvant |
CA2585672A1 (fr) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Approches combinatoires destinees a produire des reponses immunitaires |
AU2005316476A1 (en) * | 2004-12-15 | 2006-06-22 | University Of Florida Research Foundation, Inc. | Chimeric vectors |
US20100098721A1 (en) * | 2006-10-18 | 2010-04-22 | St. Jude Children's Reseach Hospital | Methods and compositions for preparing a universal influenza vaccine |
WO2010093784A2 (fr) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci |
EA025417B1 (ru) * | 2010-11-22 | 2016-12-30 | Борис Славинович ФАРБЕР | Вакцины с повышенной иммуногенностью и способы их получения |
US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
DK2694101T3 (en) | 2011-04-06 | 2017-01-09 | Biovaxim Ltd | Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans |
RU2014124154A (ru) | 2011-11-14 | 2015-12-27 | Новартис Аг | Иммуногенные комплексы полианионных карбомеров и полипептидов env и способы их получения и применения |
US9833503B2 (en) | 2012-02-24 | 2017-12-05 | President And Fellows Of Harvard College | Methods for displaying polypeptides and uses thereof |
PT3390430T (pt) * | 2015-12-15 | 2019-11-20 | Janssen Vaccines & Prevention Bv | Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização |
CN113874078A (zh) | 2019-04-05 | 2021-12-31 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198214A (en) * | 1983-08-31 | 1993-03-30 | Stolle Research & Development Corporation | Anti-mastitis polyvalent vaccine, method of administration and method for production thereof |
GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
US5169763A (en) * | 1986-04-08 | 1992-12-08 | Transgene S.A., Institut Pasteur | Viral vector coding glycoprotein of HIV-1 |
IL82104A0 (en) * | 1986-04-08 | 1987-10-30 | Usa | Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins |
US5081226A (en) * | 1986-12-30 | 1992-01-14 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic peptides sharing sequence homology with the HIV envelope protein |
ATE160377T1 (de) * | 1989-04-18 | 1997-12-15 | Applied Biotechnology Inc | Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren |
AU672581B2 (en) * | 1991-03-07 | 1996-10-10 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
EP1170368B1 (fr) * | 1994-01-27 | 2010-07-28 | University Of Massachusetts Medical Center | Immunisation par inoculation d'une unité de transcription d'ADN |
FR2728794B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro |
-
1996
- 1996-01-23 US US08/590,288 patent/US5741492A/en not_active Expired - Lifetime
-
1997
- 1997-01-23 RO RO98-01218A patent/RO120268B1/ro unknown
- 1997-01-23 BR BR9707611A patent/BR9707611A/pt not_active Application Discontinuation
- 1997-01-23 AP APAP/P/1998/001325A patent/AP1200A/en active
- 1997-01-23 UA UA98084523A patent/UA73712C2/uk unknown
- 1997-01-23 EP EP97903823A patent/EP0876498B1/fr not_active Expired - Lifetime
- 1997-01-23 AU AU18299/97A patent/AU709174B2/en not_active Ceased
- 1997-01-23 IL IL125497A patent/IL125497A/en not_active IP Right Cessation
- 1997-01-23 HU HU9900389A patent/HU224344B1/hu not_active IP Right Cessation
- 1997-01-23 CZ CZ0229398A patent/CZ296575B6/cs not_active IP Right Cessation
- 1997-01-23 ES ES97903823T patent/ES2230596T3/es not_active Expired - Lifetime
- 1997-01-23 JP JP9526911A patent/JP2000504326A/ja active Pending
- 1997-01-23 NZ NZ331024A patent/NZ331024A/en not_active IP Right Cessation
- 1997-01-23 WO PCT/US1997/000669 patent/WO1997027311A1/fr active IP Right Grant
- 1997-01-23 GE GEAP19974458A patent/GEP20032902B/en unknown
- 1997-01-23 HU HU0402182A patent/HU0402182D0/hu unknown
- 1997-01-23 PT PT97903823T patent/PT876498E/pt unknown
- 1997-01-23 CA CA002243570A patent/CA2243570C/fr not_active Expired - Fee Related
- 1997-01-23 US US08/788,815 patent/US5846546A/en not_active Expired - Lifetime
- 1997-01-23 AT AT97903823T patent/ATE278790T1/de active
- 1997-01-23 DE DE69731075T patent/DE69731075T2/de not_active Expired - Lifetime
- 1997-01-23 EP EP03077363A patent/EP1378516A1/fr not_active Ceased
- 1997-01-23 CN CNB971932344A patent/CN1229501C/zh not_active Expired - Fee Related
- 1997-01-23 TR TR1998/01418T patent/TR199801418T2/xx unknown
- 1997-01-23 KR KR1019980705646A patent/KR100571479B1/ko not_active IP Right Cessation
- 1997-01-23 IL IL15691997A patent/IL156919A0/xx unknown
- 1997-01-23 EA EA199800638A patent/EA002390B1/ru not_active IP Right Cessation
- 1997-01-23 DK DK97903823T patent/DK0876498T3/da active
- 1997-01-23 PL PL97328193A patent/PL188641B1/pl unknown
-
1998
- 1998-07-22 NO NO19983377A patent/NO322261B1/no not_active IP Right Cessation
- 1998-07-22 OA OA9800118A patent/OA10814A/en unknown
- 1998-08-21 BG BG102712A patent/BG64711B1/bg unknown
- 1998-09-21 US US09/157,963 patent/US6086891A/en not_active Expired - Lifetime
-
1999
- 1999-03-24 HK HK99101230A patent/HK1016218A1/xx not_active IP Right Cessation
-
2007
- 2007-07-17 JP JP2007186200A patent/JP2007259870A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL125497A0 (en) | Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv | |
EP0717636A4 (fr) | Vaccin a poxvirus recombine contre le paludisme | |
IL127872A0 (en) | Analogs of cationic proteins | |
AU4071595A (en) | Live recombinant avian vaccine using an avian herpesvirus as vector | |
GB9303023D0 (en) | Flavivirus recombinant poxvirus vaccine | |
PL330869A1 (en) | Non-aqueous protical peptide preparations | |
PL330903A1 (en) | Aqueous preparations of peptides | |
EP0708658A4 (fr) | Vaccin contenant un cytomegalovirus de recombinaison | |
AU3309997A (en) | Recombinant adeno-associated viral vectors | |
GB8821528D0 (en) | Recombinant vaccinia virus | |
HUP9902710A3 (en) | Recombinant swinepox virus | |
ZA9810774B (en) | Use of P102 as a recombinant mycoplasma hypopneumoniae vaccine | |
IL101639A0 (en) | Recombinant influenza vaccines | |
EP0710120A4 (fr) | Suipoxvirus recombine | |
EP0897391A4 (fr) | Antigenes recombinants utiles pour le serodiagnostic de l'infection a neospora | |
GB9615022D0 (en) | Vaccine preparations | |
IL124542A0 (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
AU5597998A (en) | Recombinant plague vaccine | |
IL115197A0 (en) | Vaccine preparations | |
GR3029513T3 (en) | Peptides inhibiting the release of pepsine | |
AU8132287A (en) | Recombinant vaccinia virus | |
AU5397598A (en) | Vaccine preparation for the reversible immunocastration of mammals | |
ZA974780B (en) | Intermediates for the preparation of peptide analogues. | |
ZA971289B (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
IL156970A0 (en) | Analogs of cationic proteins |